生物防御/新发感染疫苗研究-猫眼课题宝

生物防御/新发感染疫苗研究

批准号：

9562820

负责人：

Julie E. Ledgerwood

金额：

$467.47万

依托单位：

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

依托单位国家：

美国

项目类别：

财政年份：

资助国家：

美国

项目状态：

未结题

起止时间：

至

来源：

https://reporter.nih.gov/project-details/9562820

关键词：

Adenovirus Vector Adenoviruses Adult Alphavirus Animal Model Antibodies Antibody titer measurement Attenuated Avian Influenza Clinical Data Clinical Research Clinical Trials Clinical assessments Collaborations Communicable Diseases DNA DNA Vaccines Data Analyses Dose Ebola Vaccines Ebola virus Enrollment Evaluation Ferritin Filoviridae Filovirus Frankfurt-Marburg Syndrome Virus Future Generations Genes Glycoproteins HIV Hemagglutinin Human Immune Inactivated Vaccines Individual Indonesia Infection Influenza Influenza A Virus, H5N1 Subtype Influenza A virus Influenza Hemagglutinin International Intramuscular Intravenous Investigation Malaria Malaria Vaccines Military Personnel Mission Monoclonal Antibodies Pan Genus Phase Phase I Clinical Trials Plasmodium falciparum vaccine Production Protein Subunits Publishing Radiation Recombinants Regimen Research Route Safety Schedule Science Severe Acute Respiratory Syndrome Sporozoite vaccine T cell response Uganda Universities Vaccines Virus-like particle West Nile virus Zika Virus base biodefense chikungunya defective adenoviral vector follow-up immunogenic immunogenicity intravenous administration malaria infection neutralizing antibody pandemic disease pandemic influenza pathogen phase 1 study phase I trial phase II trial preclinical study programs response seasonal influenza vaccine candidate vaccine evaluation vaccine trial vector

项目摘要

项目成果

Julie E. Ledgerwood的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

Evaluation of the investigational vaccines in this project are part of the VRC mission related to biodefense and emerging pathogens. In FY15 this project included clinical assessments and data analysis for clinical trials of investigational vaccines against several infectious diseases including filoviruses (Ebola) and influenza (seasonal and pandemic strains). Further evaluation of vaccine approaches will continue as the VRC develops additional candidate vaccine regimens. Published results from clinical trials have included: VRC 204: Ebola DNA vaccine study: Clin Vaccine Immunol. 2006. 13(11):1267-77 VRC 302: West Nile virus DNA vaccine study: J Infect Dis. 2007. 196(12):1732-40 VRC 301: SARS DNA vaccine study () Vaccine. 2008 Nov 25;26(50):6338-43 VRC 303: Second generation West Nile virus DNA vaccine study: J Infect Dis. 2011, May 15;203(10) VRC 205: Second generation Ebola rAd5 vaccine study: Vaccine. 2010 Oct 27 VRC 306: H5N1 gene based prime, inactivated boost study Lancet Infect Dis. 2011 Dec;11(12):916-24 VRC 304 and VRC 305: H5 DNA vaccine study and H5 route study: Clin Vaccine Immunol. 2012 Nov; 19(11):1792-7 VRC 310: Follow on H5N1 prime, inactivated boost interval examination study: J Infect Dis. 2013 Aug 1; 208(3):413-7, J Infect Dis. 2013 Aug 1; 208(3):418-22 VRC 312: Dose-escalation with experimental challenge to evaluate intravenous administration of PfSPZ vaccine trial: Science. 2013 Sep 20;341(6152):1359-65 VRC 311: a VLP vaccine for Chikungunya: Lancet. 2014 Aug 14 VRC 206: Ebola and Marburg vaccine study: J Infect Dis. 2015 Feb 15;211(4):549-57 VRC 207: cAd3-EBO Ebola vaccine study: N Engl J Med. 2014 Nov 26 RV 247: Ebola and Marburg vaccine study in Uganda: Lancet. 2015 Apr 18;385(9977):1545-54 VRC 308: Pandemic H1 DNA vaccine study: PLoS One. 2015 Apr 17;10(4):e0123969 VRC 701: DNA Priming for Seasonal Influenza vaccine study: PLoS One. 2015 May 7;10(5):e0125914 VRC 307 and VRC 309: Seasonal Influenza HA DNA Followed by TIV Boost vaccine study: Contemp Clin Trials. 2015 Aug 11 VRC 314: Experimental controlled human malaria infections to evaluate safety and durability following intravenous and intramuscular administration of PfSPZ vaccine in malaria-naive adults: Nat Med. 2016 Jun;22(6):614-23.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文